Scotiabank Notes Bristol-Myers Squibb Company (BMY) as Appealing Investment in 2026

We recently compiled a list of the Top 10 Oncology Stocks to Buy Now. Bristol-Myers Squibb Company  is placed second among the best cancer stocks on our list.

TheFly reported on January 9 that Scotiabank analyst Louise Chen raised BMY’s price target to $60 from $53 while maintaining a Sector Perform rating. According to the analyst, investors find the stock appealing because to its low valuation and a “catalyst-rich” 2026.

Separately, on January 12, Bristol-Myers Squibb Company (NYSE:BMY) announced that its Phase 3 SCOUT-HCM trial, which assessed Camzyos (mavacamten) in teenagers with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), yielded positive topline results. With a safety profile comparable to that of adults, the study, the first Phase 3 evaluation of a cardiac myosin inhibitor in patients with oHCM aged 12 to <18, fulfilled its primary and many secondary endpoints.

Bristol-Myers Squibb Company (NYSE:BMY) is a global biopharmaceutical leader in oncology, advancing innovative immuno-oncology and targeted therapies across solid tumors and hematologic malignancies, supported by a deep clinical pipeline and a strong legacy in cancer research and development.

While we acknowledge the potential of BMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.